The report provides detailed data on partnership and licensing transactions, Merger and Acquisition s, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals market in October 2010. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides data on the top financial advisory firms in the pharmaceuticals market .

Data presented in this report is derived from Industry expert's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Research Scope

- Analysis of the industry trends for the pharmaceutical market in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health sectors .
- Analysis of partnerships, licensing, Merger and Acquisition s, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical market .
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and Merger and Acquisition s.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical market .
- Analysis of partnership and licensing deals based on clinical stage of development of products.
-

What's inside this report? of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical market .
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in Merger and Acquisition s and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Why Should You Get This Report?

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing sectors for investments in your market .
- Evaluate the types of industry players which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify industry players that are aggressively looking to raise capital in the industry
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical market .
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech firms .
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical market .
- Identify growth sectors and opportunities in each region within the market .
- Look for key financial advisors where you are planning to raise capital from the industry or for take over s within the market .

Table Of Contents

1 Table of Contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 6

II Deal Summary 8
II. 1 Pharmaceuticals and Healthcare, World Deals Analysis, 2010 8
II. 2 Pharmaceuticals and Healthcare, Global, Top Deals, 2010 10
II. 2.1 Pfizer Commences Tender Offer To Take Over King Pharmaceuticals 10
II. 2.2 Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics 10
II. 2.3 Bain Capital To Take Over Priory 10
II. 2.4 DaVita Announces Pricing Of Underwritten Public Offering Of Senior Notes For US$ 1.6 billion 10
II. 3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, 2010 11

III Pharmaceuticals and Healthcare, Merger and Acquisition Deal Summary, by Type 12
III. 1 Pharmaceuticals and Healthcare, Global, Merger and Acquisition, 2010 12
III. 1.1 Top Merger and Acquisition Deals in 2010 13
III. 1.2 Pharmaceuticals and Healthcare, World MandA Deals by Therapy Area, May 2010 - 2010 14
III. 2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, 2010 15
III. 2.1 Top Equity Offering Deals in 2010 16
III. 2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, May 2010 - 2010 17
III. 3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, 2010 18
III. 3.1 Top Debt Offering Deals in 2010 19
III. 3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, May 2010 - 2010 20
III. 4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, 2010 21
III. 4.1 Top PE/VC Deals in 2010 22
III. 4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, 2010 23
III. 4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, 2010 24
III. 4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, May 2010 - 2010 25
III. 4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Firms, May 2010 - 2010 26

IV Pharmaceuticals and Healthcare, Global, Partnership Deals, 2010 27
IV. 1 Pharmaceuticals and Healthcare, Global, Partnership Deals, 2010 27
IV. 2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, May 2010 - 2010 28
IV. 3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), 2010 29
IV. 3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, 2010 30
IV. 4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 31
IV. 5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), May 2010 - 2010 32
IV. 6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 33

V Pharmaceuticals and Healthcare, Global, Licensing Agreements, 2010 34
V. 1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, 2010 34
V. 2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), 2010 35
V. 2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, 2010 36
V. 2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, 2010 36
V. 2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, 2010 37
V. 3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Value (US$ m), May 2010 - 2010 38
V. 4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2010 - 2010 39
V. 5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2010 - 2010 40
V. 6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2010 - 2010 41

VI Deal Summary by Therapy Area 42
VI. 1 Pharmaceuticals and Healthcare, Oncology Deals, 2010 42
VI. 1.1 Oncology - Deals of the Month 43
VI. 2 Pharmaceuticals and Healthcare, Central Nervous System Deals, 2010 44
VI. 2.1 Central Nervous System - Deals of the Month 45
VI. 3 Pharmaceuticals and Healthcare, Immunology Deals, 2010 46
VI. 3.1 Immunology - Deals of the Month 47
VI. 4 Pharmaceuticals and Healthcare, Infectious Disease Deals, 2010 48
VI. 4.1 Infectious Diseases - Deals of the Month 49
VI. 5 Pharmaceuticals and Healthcare, Cardiovascular Deals, 2010 50
VI. 5.1 Cardiovascular - Deals of the Month 51
VI. 6 Pharmaceuticals and Healthcare, Metabolic Disorders Deals, 2010 52
VI. 6.1 Metabolic Disorders - Deals of the Month 53
VI. 7 Pharmaceuticals and Healthcare, Gastrointestinal Deals, 2010 54
VI. 7.1 Gastrointestinal - Deals of the Month 55

VII Deal Summary by Geography 56
VII. 1 Pharmaceuticals and Healthcare, North America, Regional Deals, 2010 56
VII. 1.1 North America - Deals of the Month 57
VII. 2 Pharmaceuticals and Healthcare, Europe, Regional Deals, 2010 58
VII. 2.1 Europe - Deals of the Month 59
VII. 3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, 2010 60
VII. 3.1 Asia-Pacific - Deals of the Month 61
VII. 4 Pharmaceuticals and Healthcare, Rest of the World Deals, 2010 62
VII. 4.1 Rest of the World - Deals of the Month 63

VIII Pharmaceuticals and Healthcare, Top Advisors 64
VIII. 1 Pharmaceuticals and Healthcare, World Top Financial Advisors, Merger and Acquisition, May 2010 - 2010 64
VIII. 2 Pharmaceuticals and Healthcare, Top Financial Advisors, Equity Offerings, May 2010 - 2010 65

IX Further Information 66
IX. 1 Methodology 66
IX. 2 About GlobalData 66
IX. 3 Contact Us 67
IX. 4 Disclosure information 67
IX. 5 Disclaimer 671.1 List of Data tables
Data table 1: Pharmaceuticals and Healthcare, Global, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 9
Data table 2: Pharmaceuticals and Healthcare, Global, Top Deals, 2010 10
Data table 3: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), 2010 11
Data table 4: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 12
Data table 5: Pharmaceuticals and Healthcare, Global, Top Merger and Acquisition Deals, 2010 13
Data table 6: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2010 - 2010 14
Data table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 15
Data table 8: Pharmaceuticals and Healthcare, Global, Top Equity Offering Deals, 2010 16
Data table 9: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 17
Data table 10: Pharmaceuticals and Healthcare, Global, Debt Offerings, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 18
Data table 11: Pharmaceuticals and Healthcare, Global, Top Debt Offering Deals, 2010 19
Data table 12: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Value (US$ m), May 2010 - 2010 20
Data table 13: Pharmaceuticals and Healthcare, Global, PE/VC, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 21
Data table 14: Pharmaceuticals and Healthcare, Global, Top PE/VC Deals, 2010 22
Data table 15: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Merger and Acquisition Deal Summary, May 2010 - 2010 23
Data table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), 2010 24
Data table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2010 - 2010 25
Data table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Firms, May 2010 - 2010 26
Data table 19: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2010 - 2010 27
Data table 20: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2010 - 2010 28
Data table 21: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 29
Data table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), 2010 30
Data table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 31
Data table 24: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, May 2010 - 2010 32
Data table 25: Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal Value (US$ m), May 2010 - 2010 33
Data table 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 34
Data table 27: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Merger and Acquisition Deal Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 35
Data table 28: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Deal Value, 2010 36
Data table 29: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payment, 2010 36
Data table 30: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, 2010 37
Data table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Value (US$ m), May 2010 - 2010 38
Data table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), 2010 39
Data table 33: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, May 2010 - 2010 40
Data table 34: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), 2010 41
Data table 35: Pharmaceuticals and Healthcare, Global, Oncology, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 43
Data table 36: Pharmaceuticals and Healthcare, Global, Central Nervous System, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 44
Data table 37: Pharmaceuticals and Healthcare, Global, Immunology Diseases, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 46
Data table 38: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 48
Data table 39: Pharmaceuticals and Healthcare, Global, Cardiovascular, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 50
Data table 40: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 52
Data table 41: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 54
Data table 42: Pharmaceuticals and Healthcare, North America, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 57
Data table 43: Pharmaceuticals and Healthcare, Europe, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 59
Data table 44: Pharmaceuticals and Healthcare, Asia-Pacific, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 61
Data table 45: Pharmaceuticals and Healthcare, Rest of the World, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 62
Data table 46: Pharmaceuticals and Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Values (US$ m), May 2010 - 2010 64
Data table 47: Pharmaceutical and Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2010 - 2010 651.2

List of Figures

Chart 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2010 - 2010 8
Chart 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),October ober 2010 11
Chart 3: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Number of Deals and Deal Values (US$ m), May 2010 - 2010 12
Chart 4: Pharmaceuticals and Healthcare, Global, Merger and Acquisition by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2010 - 2010 14
Chart 5: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2010 - 2010 15
Chart 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2010 - 2010 17
Chart 7: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), May 2010 - 2010 18
Chart 8: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), May 2010 - 2010 20
Chart 9: Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2010 - 2010 21
Chart 10: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2010 - 2010 23
Chart 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), 2010 24
Chart 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2010 - 2010 25
Chart 13: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2010 - 2010 27
Chart 14: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2010 - 2010 28
Chart 15: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), May 2010 - 2010 29
Chart 16: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 31
Chart 17: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, May 2010 - 2010 32
Chart 18: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 33
Chart 19: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2010 - 2010 34
Chart 20: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 35
Chart 21: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Value (US$ m), May 2010 - 2010 38
Chart 22: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2010 - 2010 39
Chart 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), May 2010 - 2010 40
Chart 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), 2010 41
Chart 25: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2010 - 2010 42
Chart 26: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2010 - 2010 44
Chart 27: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2010 - 2010 46
Chart 28: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2010 - 2010 48
Chart 29: Pharmaceuticals and Healthcare, Global, Cardiovascular, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 50
Chart 30: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), May 2010 - 2010 52
Chart 31: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Number of Deals and Deal Values (US$ m), May 2010 - 2010 54
Chart 32: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2010 - 2010 56
Chart 33: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2010 - 2010 58
Chart 34: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2010 - 2010 60
Chart 35: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2010 - 2010 62
Chart 36: Pharmaceuticals and Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Values (US$ m), May 2010 - 2010 64
Chart 37: Pharmaceuticals and Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2010 - 2010 65

Companies mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Global Medical Specialty Bags Market

Global Medical Specialty Bags Market

  • $ 4 950
  • Industry report
  • May 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Medical Specialty Bags in US$ Thousands by the following Product Segments: Bile Collection Bags, Blood Bags, Breathing Bags, Cadaver Bags, Enema Bags, Enteral ...

Regenerative Medicine Market (Bone and Joint) (By Technology - By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products & Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013

Regenerative Medicine Market (Bone and Joint) (By Technology - By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products & Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013

  • $ 4 795
  • Industry report
  • July 2014
  • by Transparency Market Research

U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital ...

Regenerative Medicine Market (Bone and Joint) (By Technology - By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products...) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019

Regenerative Medicine Market (Bone and Joint) (By Technology - By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products...) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • July 2014
  • by Transparency Market Research

U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.